Beyond headlines and amyloid, the Alzheimer’s pipeline chugs along
Three therapeutics for Alzheimer’s disease steal the headlines at the moment: Eisai and Biogen’s lecanemab, Genentech’s gantenerumab and Eli Lilly’s donanemab.
All Posts in "News Team"
Medtronic’s new MiniMed insulin pump adds 27% boost to time in range, study finds
As Medtronic continues to await FDA clearance of the latest iteration of its MiniMed insulin pump, the medtech giant has churned out a steady stream of data supporting the device’s ability to improve outcomes for Type 1 diabetes patients.
Vibrant Gastro passes vibrating constipation pill through FDA review
Fresh off reporting promising results from a phase 3 study of its constipation relief device, Vibrant Gastro is keeping things moving.
Uncovering a link between lung cancer and chronic pain—and a druggable pathway for both
Scientists have uncovered a link between chronic pain and lung cancer—a link that also offers a potentially druggable pathway for both conditions, according to new research conducted in mouse models.
Novo Nordisk ponies up $1.1B for Forma in effort to shape up sickle cell disease market
Novo Nordisk is handing over $1.1 billion in cash to buy Forma Therapeutics in hopes that the clinical-stage biotech’s assets will help build a leading portfolio in sickle cell disease (SCD).
As EU challenge intensifies, Illumina clocks a stateside win in FTC antitrust case over Grail buy
An administrative law judge ruled in Illumina’s favor Thursday in the U.S. Federal Trade Commission’s (FTC’s) challenge to the DNA sequencing giant’s acquisition of blood test maker Grail.
Finch axes more than a 3rd of its workforce days after Takeda clips its fiscal wings
A week after taking back two unhatched inflammatory bowel assets from Takeda, Finch Therapeutics is cutting more than a third of its staff and delaying clinical trial plans to stave off rising costs.
Novartis R&D chief Jay Bradner bids adieu to the Swiss Big Pharma
The leadership and staffing shake-ups at Novartis continue to define the company’s year, with one of the most significant names yet electing to move on.
AnaptysBio’s HARP plays dud note, prompting rethink of imsidolimab strategy
AnaptysBio’s stuttering effort to rebuild its pipeline around imsidolimab has hit another setback. After flopping in palmoplantar pustulosis and acne, the anti-IL-36 receptor antagonist has failed to move the needle in the chronic skin disease hidradenitis suppurativa, leading the biotech to stop work on one indication and plan to out-license the asset.
As activist investor ratchets up pressure, Mereo makes more cuts to extend cash runway into 2025
Mereo BioPharma, under pressure from an activist investor, has reduced its head count to stretch its cash runway out into the second quarter of 2025. The biotech disclosed the cuts in a rebuttal to Rubric Capital Management’s “low-risk strategy” for unlocking the value of its assets while preserving cash.
Beyond headlines and amyloid, the Alzheimer’s pipeline chugs along
Medtronic’s new MiniMed insulin pump adds 27% boost to time in range, study finds
Vibrant Gastro passes vibrating constipation pill through FDA review
Uncovering a link between lung cancer and chronic pain—and a druggable pathway for both
Novo Nordisk ponies up $1.1B for Forma in effort to shape up sickle cell disease market
As EU challenge intensifies, Illumina clocks a stateside win in FTC antitrust case over Grail buy
Finch axes more than a 3rd of its workforce days after Takeda clips its fiscal wings
Novartis R&D chief Jay Bradner bids adieu to the Swiss Big Pharma
AnaptysBio’s HARP plays dud note, prompting rethink of imsidolimab strategy
As activist investor ratchets up pressure, Mereo makes more cuts to extend cash runway into 2025